abstract PURPOSE Genetic testing for cancer risk has expanded rapidly. We examined clinical genetic testing and results among population-based patients with breast and ovarian cancer.
INTRODUCTION
Germline genetic testing has become an integral part of the care of patients with breast and ovarian cancer and their families since BRCA1 and BRCA2 (BRCA1/2) were identified in 1994 to 1995. 1, 2 Epidemiologic studies have defined the prevalence of BRCA1/2 pathogenic variants in patient subgroups such as triple-negative breast cancer (TNBC), pancreatic cancer, and prostate cancer, [3] [4] [5] and testing guidelines have evolved. 6 Recent advances in nextgeneration technology and regulatory changes have enabled sequencing of more genes at a lower cost using multiple-gene panels. [7] [8] [9] Studies in clinic-based samples suggest that multiplegene sequencing panels may double the prevalence of pathogenic variants detected by testing BRCA1/2 alone. [10] [11] [12] [13] [14] [15] [16] However, such studies often used convenience samples limited to a single institution or laboratory. Almost nothing is known about the prevalence of pathogenic variants on multiple-gene panels among clinically tested, population-based patients with breast cancer and patients with ovarian cancer. Yet, such knowledge is essential to inform population-wide health policy, resource planning, and development of testing guidelines.
We established the Georgia-California Surveillance, Epidemiology and End Results (SEER) Genetic Testing Linkage Initiative with the SEER registries of Georgia and California and the four laboratories that performed nearly all cancer susceptibility testing in these regions during the study period. In this article, we examine testing use and results among all patients with breast cancer (N = 77,085) and all patients with ovarian cancer (N = 6,001) diagnosed in California and Georgia between 2013 and 2014.
METHODS

Creation of Study Cohort and Analytic Data Set
Using a third-party honest broker (Information Management Services, Rockville, MD), all female patients with breast and ovarian cancer diagnosed between 2013 and 2014 from the Georgia Cancer Registry and the California Cancer Registry were linked with germline genetic testing information from four laboratories (Ambry Genetics, Aliso Viejo, CA; GeneDx, Gaithersburg, MD; Invitae, San Francisco, CA; Myriad Genetics, Salt Lake City, UT) that performed the majority of clinical testing. Probabilistic methods were implemented to optimize linkage in the presence of uncertainty or errors in any individual linkage covariable.
The analytic data set combined testing data from all laboratories; all variables other than genetic tests and results were from SEER registries. Second or later breast or ovarian cancers in the same patient were excluded (6.1% for breast cancer; 4.3% for ovarian cancer). Patients diagnosed before 20 years of age, at death, or with unknown race were excluded (Fig 1) . Breast tumor biomarker subtype was defined by combinations of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression. Genetic test use and results were captured through the first quarter of 2016. If a patient was tested more than once, results were merged, keeping the most recent result for each gene. The combined analytic file containing both registry and laboratory information was stripped of protected health information (as defined by the Health Information Portability and Accountability Act Privacy Rule), 17 and some variables (age, race, marital status, poverty, insurance, histology, and test result) were collapsed to minimize the risk of reidentification. This study was approved by the institutional review boards associated with the SEER registries.
Testing Variables From Laboratories
Each laboratory provided results at the gene level for 139 genes, including the interpretation, according to American College of Medical Genetics criteria, 18 and sent to the ordering clinician: pathogenic or likely pathogenic (combined for analysis as pathogenic); variant of uncertain significance (VUS); and benign or likely benign (combined for analysis as normal). We categorized a test as a multiple-gene panel if it included other genes in addition to BRCA1/2, versus BRCA1/2 only. To ensure anonymity of laboratories, results from all laboratories were combined, and gene-specific results were retained in the analytic data set only for genes tested by two or more laboratories (n = 53). Results for the remaining 86 genes tested by only one laboratory were categorized collectively: pathogenic variants were rare (0% for ovarian cancer and 0.09% for breast cancer), whereas VUSs were more common (3.6% for ovarian and 2.1% for breast cancer).
Statistical Methods
We examined testing use by patient characteristics among all patients with breast cancer and all patients with ovarian cancer in Georgia and California. Gene-specific results by cancer type for a subset of genes were presented using binomial proportions with exact confidence limits. This subset included 11 genes designated by the current National Comprehensive Cancer Network guidelines as breast cancer susceptibility genes (ATM, BRCA1, BRCA2, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, and TP53), one gene designated as potentially associated with breast cancer (BARD1), and 11 genes designated as ovarian cancer susceptibility genes (BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, MSH6, PMS2, RAD51C, RAD51D, and STK11). 6 Pathogenic variants in these genes should prompt a change in care per guidelines. 6 Results were stratified by biomarker subtype (breast) and race/ethnicity (breast and ovarian). Pathogenic variant and VUS prevalence among patients tested for all 11 guideline-designated genes were examined by cancer type and race/ethnicity and tested for homogeneity by a x 2 statistic. 
RESULTS
Patient Characteristics
Genetic Testing Results Among Patients With Breast Cancer
The Data Supplement lists 53 genes tested by at least two laboratories, of which 11 are currently guideline-designated as breast cancer susceptibility genes and 11 as ovarian cancer susceptibility genes. 6 Among patients with breast cancer, three times more were tested for BRCA1 (18, 506) and BRCA2 (18,522) than any other breast cancer gene (6,842 for TP53, fewer for others; Table 2 ). Pathogenic variants were most frequently detected in BRCA1 (3.2%) and BRCA2 (3.1%), followed by CHEK2 (1.6%), PALB2 (0.96%), and ATM (0.73%; Fig 2A) . Pathogenic variants were detected in BARD1, CDH1, NBN, NF1, and TP53, and ranged from 0.14% to 0.35%. Few patients with breast cancer (n = 1,464; 1.9%) were tested for all 11 genes designated by current guidelines 6 as breast cancer susceptibility genes (Table 3) . Among patients tested for all 11 guideline-designated breast cancer genes, 7.8% had a pathogenic variant, and 17.6% had VUSs in any of these genes (Table 3 ). Significant variation of both proportions (pathogenic variant and VUS) existed by race/ethnicity.
Genetic Testing Results Among Patients With Ovarian Cancer
Among tested patients with ovarian cancer, almost twice as many were tested for BRCA1 (1,844) and BRCA2 (1,841) as for any other National Comprehensive Cancer Networkdesignated ovarian cancer gene (1,007 for MSH2, fewer for others; Table 2 ). Pathogenic variants were most prevalent in BRCA1 (8.7%) and BRCA2 (5.8%). After BRCA1/2, pathogenic variants in ovarian cancer genes were most prevalent in BRIP1 (0.92%), MSH2 (0.79%), and RAD51C (0.58%). However, pathogenic variants were similarly prevalent among patients with ovarian cancer as among patients with breast cancer in CHEK2 (1.4%) and ATM (0.64%), genes not known to confer elevated ovarian cancer risk (Fig 2B; Table 2 ). Overall, 13.7% of patients with ovarian cancer were tested for all 11 genes currently guideline-designated as ovarian cancer susceptibility genes (Table 3) . Among patients tested for all 11 guidelinedesignated ovarian cancer genes, 14.5% had a pathogenic variant, and 15.6% had VUSs in any of them.
Genetic Testing Results by Breast Cancer Subtype
Breast cancer subtype-specific differences in pathogenic variant prevalence were observed in various genes (Data Supplement). Statistically significant examples include BRCA1 (HR positive, HER2 negative: 2.1%; 95% CI, 1.8% to 2.3%; TNBC: 11.4%; 95% CI, 10.2% to 12.7%) and CHEK2 (HR positive, HER2 negative: 1.7%; 95% CI, 1.3% to 2.3%; TNBC: 0.25%; 95% CI, 0.03% to 0.90%).
Genetic Testing Results by Race/Ethnicity
There were racial/ethnic differences in pathogenic variant prevalence in various genes (Data Supplement 
DISCUSSION
To our knowledge, this is the first US study of hereditary cancer genetic testing at the population level with laboratory-confirmed testing results. We took advantage of SEER registries that cover the entire populations of California and Georgia, two regions of racial/ethnic and socioeconomic diversity that together comprise approximately 50 million people. We investigated the clinical use of genetic testing from the four major laboratories that provide it in the regions under study. We found that nearly one quarter of patients with breast cancer and fewer than one third of patients with ovarian cancer diagnosed between 2013 and 2014 had germline genetic testing. Among those tested for all genes designated by current guidelines as associated with their cancer type, 7.8% of patients with breast cancer and 14.5% of patients with ovarian cancer carried a pathogenic variant that warrants a potential change in care, such as secondary breast cancer screening incorporating magnetic resonance imaging, earlier colonoscopy, or risk-reducing surgery.
6
Few population-level studies have evaluated trends, patterns, and correlates of genetic testing, and most focused on BRCA1/2 testing only. 19, 20 We previously published articles from a survey, the iCanCare study, of more than 5,000 patients diagnosed with breast cancer in 2013 to 2015 from Georgia and Los Angeles County. 9, [21] [22] [23] [24] However, that sample of testers was far too small to evaluate correlates of variants in specific genes. Furthermore, that previous study did not include patients with ovarian cancer.
In this study, our expanded population-level focus on more than 83,000 patients with breast cancer or ovarian cancer offers granular detail on testing gaps, disparities, and genespecific results at a major inflection point in the implementation of precision oncology.
The context of cancer genetic testing changed in mid-2013, after a US Supreme Court decision on gene patenting, decreasing costs, and growing public awareness. [25] [26] [27] [28] A study of medically underserved patients with breast and ovarian cancer who met criteria for Medicare coverage of BRCA1/2 testing from 2002 to 2014 reported a testing rate of 9%. 29 Our study evaluated testing from 2012 to 2016 for all California and Georgia patients with breast and ovarian cancer diagnosed in 2013 to 2014. The observed testing rate of 24% among unselected patients with breast cancer demonstrates the broad penetration of testing into community practice. We found little regional variation, suggesting that these results are broadly generalizable. We also found little racial/ethnic variability in testing of patients with breast cancer, although there was an access gradient by poverty level. Higher testing rates among patients with TNBC reflect guideline recommendations to test nearly all such patients, whereas more restrictive criteria on the basis of family history are advised for other subtypes.
6,30,31 Although testing rates were higher among younger women, rates lower than 100% for women diagnosed with breast cancer younger than 45 years of age are suboptimal.
A 30% genetic testing rate for patients with ovarian cancer is inadequate, because guidelines have recommended testing all patients with high-grade, serous ovarian cancer for a decade. 6,32,33 We could not isolate high-grade serous cancers within this data set, but 39.2% testing among patients with tumors in the combined categories of cystic, mucinous, and serous suggests a major shortfall. Furthermore, large differences in testing rates across stage and grade subgroups suggest inappropriate targeting of testing that is indicated for all. Low testing rates among patients with earlier-stage ovarian cancer, who may survive this diagnosis, reflect a missed opportunity to provide risk-adapted screening for second cancers, such as breast, colon, and melanoma associated with pathogenic variants in specific ovarian cancer susceptibility genes. Substantial undertesting of patients with ovarian cancer may reflect their high morbidity and/or a relatively low public awareness of and advocacy for ovarian cancer. We report on a period just before US Food and Drug Administration approval of the first BRCA1/2-targeted therapy for ovarian cancer, the poly (ADP-ribose) polymerase inhibitor olaparib, in December 2014. 34 With three poly (ADP-ribose) polymerase inhibitors now approved for BRCA1/2-associated ovarian cancer, [34] [35] [36] two for BRCA1/2-associated metastatic breast cancer, 37, 38 and other targeted agents in development, 39 appropriate testing of patients with metastatic breast and/or ovarian cancer is increasingly critical both for them and to inform their at-risk relatives. Finally, the large socioeconomic disparities in test receipt after ovarian cancer diagnosis highlight the challenges of ensuring universal testing access.
Among patients tested for all genes that current guidelines designate for their cancer type, 7.8% of patients with breast cancer and 14.5% of patients with ovarian cancer carried at least one pathogenic variant that warrants a potential change in care. 6 These results do not constitute a true population prevalence among all patients with breast and ovarian cancer: patients were undoubtedly selected for testing according to clinician knowledge, patient preferences, and access factors. 8, 23, 24, 28, 40, 41 Instead, these prevalence estimates apply to the average patient with breast or ovarian cancer who undergoes testing as implemented in community practice; thus, they are highly relevant for genetic counseling. Notably, only a small minority of 2013 to 2014 patients were tested for all genes designated by current guidelines as associated with their cancer type, reflecting the fact that testing and guidelines have rapidly evolved. Moreover, guidelines do not definitively endorse multiple-gene testing for all patients for whom BRCA1/2 testing is advised. We previously reported rapid replacement of BRCA1/2-only with multiple-gene panel testing in a subsample of patients, 9 concurrent with the falling costs of sequencing. Thus, our prevalence estimates for non-BRCA1/2 genes have a smaller denominator of tested patients than we would expect today. As the population of tested patients changes over time †Significant variation existed in pathogenic variant (x 2 P , .05 for breast; P , .001 for ovary) and VUS prevalence by race/ethnicity (x 2 P , .001 for both). American Indians were excluded from the assessment because of small sample size.
(eg, if patients with less family history of breast and/or ovarian cancers are increasingly tested for more genes), prevalence estimates for both higher-risk genes (eg, PALB2) and lower-risk genes (eg, ATM) may shift.
Testing guidelines were developed to identify carriers of BRCA1/2 pathogenic variants. 6 As data emerge about the clinical presentation of other pathogenic variants, guidelines should evolve. For example, although current guidelines state that BARD1 pathogenic variants (found here in 0.2% of patients with breast cancer) have insufficient evidence to guide management, 6 recent results showing a four-to five-fold associated increase in TNBC risk may inform future guidelines. 3 Among patients with breast cancer, pathogenic variants in ATM, CHEK2, and PALB2 were relatively common, with prevalence approximately 1% each; these results resemble those of prior studies. 11, 12, 15, 16, 30 However, we observed similar frequencies of ATM, CHEK2, and PALB2 pathogenic variants among patients with ovarian cancer, although most studies have not reported an ovarian cancer risk association with these genes. 16, 42, 43 The prevalence of ATM, CHEK2, and PALB2 pathogenic variants among patients with ovarian cancer may merely reflect their relatively high population carrier frequency, but additional study of their ovarian cancer risk association is warranted. Pathogenic variants in BRIP1, MSH2, and RAD51C also approached 1% prevalence each among patients with ovarian cancer, consistent with their guideline designation as ovarian cancer susceptibility genes. 6 We observed little racial/ethnic variation in overall pathogenic variant prevalence, but did see differences by specific gene: significantly more CHEK2 pathogenic variants among whites than blacks, and more BRCA1 pathogenic variants among Hispanics. The prevalence of CHEK2 pathogenic variants among whites likely reflects the Central European1100delC founder variant. 44, 45 Others have noted a high BRCA1 pathogenic variant prevalence in Hispanic and black patients with breast cancer. 46 Another racial/ethnic difference is VUS rates, more common in blacks, Asians, and Hispanics than whites. We and others previously reported that this VUS difference likely reflects racial bias in the definition of the normal gene sequence along with less clinical testing of minority patients, 9, [47] [48] [49] [50] because an access disparity perpetuates a genetic information disparity. Ongoing efforts in germline VUS reclassification 51, 52 are essential to promoting equity in cancer care.
Our study has limitations. Results are from two states only and may not be fully generalizable elsewhere, although the scant regional variation we observed is reassuring. The time period is limited (patients diagnosed in 2013 to 2014, with results complete through March 2016), with ongoing linkage under way. Some tests may have been missed because of incomplete ascertainment or uncertainty in the linkage process. However, we surveyed genetic counselors in both states who responded that the collaborating laboratories performed nearly all relevant testing in 2013 to 2014. Furthermore, testing rates from data linkage closely approximate those of patient self-report in our prior work. 23, 24 We did not include laboratories that offer directto-consumer testing with an out-of-pocket charge; had we done so, we might have observed a magnification of the reported socioeconomic testing disparities. Finally, SEER registries do not collect data on family cancer history, which influences receipt of testing.
Clinical practice and health policy on germline genetic testing of patients with cancer are evolving rapidly as studies on the utility of genetic surveillance continue to emerge.
3,37-39,51,53-57 Some have called for populationbased testing, either of all people or of all patients with breast cancer. [57] [58] [59] Although it is possible that universal testing guidelines might reduce disparities, our results demonstrate the challenges of adhering to such inclusive guidelines in the case of ovarian cancer. Many factors conspire to limit genetic testing in those with clinical indications, including patients' and clinicians' attitudes about the value of genetic testing and the challenges of integrating genetic testing into the cancer treatment workflow. In particular, the surge in multiple-gene panel testing has markedly increased the demand for timely genetic expertise in the face of a limited supply of genetic counselors. More research is needed to identify optimal approaches to genetic testing delivery and results management and determine the impact of the rapidly changing landscape of genetic risk evaluation on patients with cancer and their families.
